Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study
Table 3
Comparison of the difference to each index between groups after treatment for 52 weeks.
Exenatide
Dulaglutide
Insulin glargine
Placebo
Exenatide vs. dulaglutide
Exenatide vs. insulin glargine
Exenatide vs. placebo
Dulaglutide vs. insulin glargine
Dulaglutide vs. placebo
Insulin glargine vs. placebo
▲
Body weight (kg)
0.016
0.116
0.002
0.565
0.097
0.318
0.012
BMI (kg/m2)
0.010
0.110
0.001
0.479
0.068
0.371
<0.001
HbA1c
<0.001
0.018
0.138
0.029
0.583
<0.001
0.002
TC (mmol/L)
0.207
0.595
0.952
0.126
0.709
0.047
0.185
TG (mmol/L)
0.611
0.910
0.622
0.347
0.210
0.422
0.210
BMD-L1 (g/cm2)
0.077
0.478
0.770
0.014
0.765
0.084
0.076
BMD-L2 (g/cm2)
0.043
0.898
0.070
0.183
0.107
0.157
0.005
BMD-L3 (g/cm2)
0.332
0.862
0.476
0.203
0.417
0.285
0.083
BMD-L4 (g/cm2)
0.01 (-0.03, 0.03)
0.12 (0.03, 0.27)
0.24 (0.11, 0.40)
0.01 (-0.04, 0.03)
0.015
<0.001
0.001
0.653
0.343
<0.001
0.001
BMD-L1-L4 (g/cm2)
0.091
0.345
0.846
0.017
0.560
0.152
0.070
BMD-femoral neck (g/cm2)
0.003
0.062
0.206
0.005
0.741
0.056
0.049
BMD-total hip (g/cm2)
<0.001
0.049
0.077
0.001
0.944
0.006
0.021
Abbreviation: BMI: body mass index; HbA1c: glycosylated hemoglobin; TC: total cholesterol; TG: triglycerides; BMD-L: bone mineral density of lumbar vertebrae; BMD-femoral neck: bone mineral density of femoral neck; BMD-total hip: bone mineral density of total hip; data shown as or median (first quartile, third quartile). Significant correlation values are shown in asterisk (,).
